Why test your patients?

Multiple Myeloma, Daratumumab-Specific, Immunofixation test helps multiple myeloma patients treated with daratumumab to tease out monoclonal antibody interference and monitor their response to treatment.

DARZALEX® (daratumumab; Janssen Biotech) is a CD38-directed cytolytic antibody indicated 1) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy and 2) as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent.

In patients being treated with Daratumumab, it is difficult to differentiate between the endogenous myeloma protein (M protein) and the daratumumab protein with immunofixation electrophoresis assay.

Quest Diagnostics has launched the FDA modified: Multiple Myeloma, Daratumumab-Specific, Immunofixation. This is a serum test detected by a gel shift assay to distinguish daratumumab from endogenous M-protein by IFE to enable assessment of the M protein.

For multiple myeloma patients being treated with Daratumumab this test can avoid unnecessary follow-up testing and allow more accurate interpretation of depth of response to treatment.

The test is available at Quest’s Nichols Institute, San Juan Capistrano, CA.